ft 19 jul 94 intern compani news us biotech group top expect revenu 21 amgen genentech incom jump threefold us two lead biotechnolog compani amgen genentech experienc strong sale second quarter year enabl record profit exceed market forecast amgen whose sale first three month year fail live expect bounc back revenu growth 21 per cent three month june dollar 414m sale neupogen treatment chemotherapi patient rose 13 per cent dollar 212m revenu epogen use connect dialysi treatment advanc 26 per cent dollar 176m june compani regulatori approv use neupogen connect high dose chemotherapi recommend increas epogen dosag packag support sale growth futur research develop spend dollar 53m dollar 64m amgen report net incom dollar 107m 77 cent share dollar 100m 70 cent share year earlier legal award ad 6 cent share earn 1993 quarter half year net incom dollar 201m dollar 190m post tax profit genentech major own roch swiss pharmaceut group jump threefold second quarter product sale rose third compani report net incom dollar 33 4m 28 cent share dollar 10 4m 9 cent year broadli line market expect behind growth product sale dollar 152m 32 per cent rise activas drug use prevent blood clot dollar 73 5m 11 per cent advanc sale compani two human growth hormon dollar 59 5m sale pulmozyn taken cystic fibrosi suffer launch first quarter reach dollar 18 7m mr kirk raab presid chief execut said activas sale growth could reinforc recent recommend food drug administr advisori committe could lead larger dosag drug taken treatment heart attack research develop spend dollar 73m dollar 84m year one charg dollar 13 7m includ spend r amp would increas second half year later stage clinic trial start number addit product genentech said half year whole net incom rose dollar 72m sale dollar 394m dollar 25m sale dollar 323m sale upjohn us pharmaceut compani slip second quarter grow gener competit biggest product slowdown howev rapid industri observ expect compani report post tax earn dollar 120m sale dollar 891m dollar 125m sale dollar 895m year earn per share 67 cent 3 cent lower correspond period comfort ahead market expect around 60 cent upjohn said us sale xanax anti anxieti treatment biggest sell drug fallen 64 per cent dollar 80m period us sale drop 8 per cent overal dollar 500m outsid us howev revenu rose 11 per cent dollar 391m buoy part higher sale xanax mr john zabriski compani recent appoint chairman chief execut point recent registr file 25 countri freedox haemorrhag treatment sign upjohn attentionto develop new product patent expiri number drug us takeov us rival syntex push upjohn top analyst list potenti takeov candid pharmaceut industri first half whole net incom fell dollar 255m dollar 1 43 share dollar 253m dollar 1 55 year